Emerging evidence implicates YY1 as a key pathogenic factor in the development of metabolic disorders, including insulin resistance, obesity, T2D, and metabolic dysfunction-associated steatotic liver disease (MASLD) (79, 210). This evidence concerns the gene YY1 and Other metabolic disease.